Denali Therapeutics (DNLI) Financials

$13.40 -0.02 (-0.15%)

As of 02:10 PM Eastern

Annual Income Statements for Denali Therapeutics

This table shows Denali Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Income / (Loss) Attributable to Common Shareholders	-421	-138	-330	-293	71	-197	-37	-88	-87
Consolidated Net Income / (Loss)	-423	-145	-326	-291	71	-198	-36	-88	-87
Net Income / (Loss) Continuing Operations	-423	-145	-326	-291	71	-198	-36	-88	-87
Total Pre-Tax Income	-423	-145	-326	-296	63	-213	-46	-88	-87
Total Operating Income	-487	-197	-341	-296	63	-213	-46	-90	-87
Total Gross Profit	0.00	331	108	49	336	27	129	0.00	0.00
Total Revenue	0.00	331	108	49	336	27	129	0.00	0.00
Operating Revenue	0.00	331	108	49	336	27	129	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	487	527	449	344	273	240	176	90	87
Selling, General & Admin Expense	105	103	90	79	60	46	32	16	12
Research & Development Expense	396	424	359	265	213	193	143	74	76
Other Special Charges / (Income)	-15	0.00	-	-	-	-	-	-	-
Total Other Income / (Expense), net	65	52	15	0.00	0.00	0.00	0.00	1.96	0.00
Interest & Investment Income	65	52	15	-	-	-	-	-	-
Income Tax Expense	0.07	0.03	0.02	-0.58	0.82	-0.35	0.00	0.00	-
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-1.38	-7.53	4.39	2.25	0.60	-1.00	0.28	-0.01	0.37
Basic Earnings per Share	($2.57)	($1.06)	($2.60)	($2.39)	$0.65	($2.07)	($0.39)	($5.89)	($13.49)
Weighted Average Basic Shares Outstanding	164.47M	137.37M	125.53M	121.52M	108.97M	95.61M	92.62M	14.96M	6.42M
Diluted Earnings per Share	($2.57)	($1.06)	($2.60)	($2.39)	$0.63	($2.07)	($0.39)	($5.89)	($13.49)
Weighted Average Diluted Shares Outstanding	164.47M	137.37M	125.53M	121.52M	112.70M	95.61M	92.62M	14.96M	6.42M
Weighted Average Basic & Diluted Shares Outstanding	145.22M	139.16M	136.68M	122.83M	108.97M	95.61M	92.62M	14.96M	6.42M

This table shows Denali Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-133	-118	-99	-100	-104	-118	-99	184	-105	-94	-103
Consolidated Net Income / (Loss)	-133	-115	-107	-99	-102	-119	-99	183	-110	-99	-103
Net Income / (Loss) Continuing Operations	-133	-115	-107	-99	-102	-119	-99	183	-110	-99	-103
Total Pre-Tax Income	-133	-115	-107	-99	-102	-119	-99	183	-110	-95	-103
Total Operating Income	-146	-130	-123	-117	-118	-133	-114	170	-121	-105	-107
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	1.27	294	35	10	3.56
Total Revenue	0.00	-	0.00	0.00	0.00	-	1.27	294	35	10	3.56
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	146	130	123	117	118	133	115	124	156	116	111
Selling, General & Admin Expense	29	30	25	25	25	25	25	26	27	24	23
Research & Development Expense	116	100	98	91	107	108	90	98	129	92	88
Other Special Charges / (Income)	0.00	-	0.00	-	-15	-	0.00	0.00	0.00	-	-
Total Other Income / (Expense), net	13	15	16	18	16	13	14	13	11	11	4.19
Interest & Investment Income	13	15	16	18	16	13	14	13	11	-	-
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.02	3.51	-8.19	1.36	1.94	-1.29	-0.79	-1.08	-4.37	-4.97	-0.42
Basic Earnings per Share	($0.78)	($0.67)	($0.63)	($0.59)	($0.68)	($0.88)	($0.72)	$1.34	($0.80)	($0.75)	($0.84)
Weighted Average Basic Shares Outstanding	171.22M	164.47M	169.46M	168.83M	149.40M	137.37M	137.64M	137.05M	136.52M	125.53M	123.47M
Diluted Earnings per Share	($0.78)	($0.67)	($0.63)	($0.59)	($0.68)	($0.84)	($0.72)	$1.30	($0.80)	($0.75)	($0.84)
Weighted Average Diluted Shares Outstanding	171.22M	164.47M	169.46M	168.83M	149.40M	137.37M	137.64M	140.93M	136.52M	125.53M	123.47M
Weighted Average Basic & Diluted Shares Outstanding	145.28M	145.22M	143.92M	143.17M	142.61M	139.16M	138.20M	137.42M	136.89M	136.68M	135.81M

This table details how cash moves in and out of Denali Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Change in Cash & Equivalents	48	-91	-75	-214	428	2.33	-140	179	9.56
Net Cash From Operating Activities	-348	-358	-245	-211	416	-152	50	-77	-72
Net Cash From Continuing Operating Activities	-348	-358	-245	-211	416	-152	50	-77	-72
Net Income / (Loss) Continuing Operations	-423	-145	-326	-291	71	-198	-36	-88	-87
Consolidated Net Income / (Loss)	-423	-145	-326	-291	71	-198	-36	-88	-87
Depreciation Expense	7.80	17	10	8.59	8.53	7.99	7.42	3.08	1.47
Amortization Expense	1.20	-44	0.00	8.75	0.06	-5.02	-2.71	0.75	0.30
Non-Cash Adjustments To Reconcile Net Income	49	104	64	82	48	40	19	4.41	8.23
Changes in Operating Assets and Liabilities, net	17	-290	7.28	-20	288	2.92	63	3.31	4.74
Net Cash From Investing Activities	-89	249	-141	-22	-623	148	-287	-41	-219
Net Cash From Continuing Investing Activities	-89	249	-141	-22	-623	148	-287	-41	-219
Purchase of Property, Plant & Equipment	-16	-13	-18	-8.50	-3.10	-18	-3.39	-2.88	-6.13
Purchase of Investments	-1,230	-1,814	-1,115	-1,423	-1,285	-370	-558	-180	-227
Sale and/or Maturity of Investments	1,157	2,076	991	1,410	665	535	274	141	14
Net Cash From Financing Activities	484	18	311	19	635	6.19	97	296	300
Net Cash From Continuing Financing Activities	484	18	311	19	635	6.19	97	296	300
Issuance of Common Equity	517	18	311	19	614	0.00	94	266	0.00
Other Financing Activities, net	-32	0.00	0.00	-	21	6.19	4.00	0.73	0.11
Cash Interest Paid	0.30	0.00	0.00	-	-	-	-	-	-
Cash Income Taxes Paid	0.00	0.00	0.05	0.21	0.00	-	-	-	-

This table details how cash moves in and out of Denali Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-116	84	16	14	-67	-21	16	64	-150	99	-36
Net Cash From Operating Activities	-131	-84	-59	-91	-114	-99	-87	-113	-59	-73	-57
Net Cash From Continuing Operating Activities	-131	-84	-59	-91	-114	-99	-87	-113	-59	-73	-57
Net Income / (Loss) Continuing Operations	-133	-115	-107	-99	-102	-119	-99	183	-110	-99	-103
Consolidated Net Income / (Loss)	-133	-115	-107	-99	-102	-119	-99	183	-110	-99	-103
Depreciation Expense	2.33	1.85	1.84	1.94	2.16	2.18	2.22	2.29	10	4.09	2.14
Amortization Expense	0.89	0.77	21	-10	-11	-44	19	-12	-7.85	-1.43	-0.69
Non-Cash Adjustments To Reconcile Net Income	20	18	-5.14	24	12	57	-5.21	26	27	-8.61	24
Changes in Operating Assets and Liabilities, net	-22	11	30	-8.16	-16	5.85	-4.41	-313	22	32	21
Net Cash From Investing Activities	19	172	94	99	-453	73	101	168	-93	-128	15
Net Cash From Continuing Investing Activities	19	172	94	99	-453	73	101	168	-93	-128	15
Purchase of Property, Plant & Equipment	-5.08	-5.09	-3.88	-4.79	-2.15	-2.24	-2.07	-5.85	-2.79	-4.85	-6.05
Purchase of Investments	-138	-174	-100	-122	-834	-414	-498	-378	-524	-487	-123
Sale and/or Maturity of Investments	162	351	198	225	383	489	601	552	434	364	144
Net Cash From Financing Activities	-3.76	-4.17	-19	6.76	500	4.71	2.49	9.02	1.60	300	5.15
Net Cash From Continuing Financing Activities	-3.76	-4.17	-19	6.76	500	4.71	2.49	9.02	1.60	300	5.15
Issuance of Common Equity	0.60	4.16	5.46	6.76	500	4.71	2.49	9.02	1.60	300	5.15
Other Financing Activities, net	-4.36	-8.32	-	-	-	-	-	-	-	-	-
Cash Interest Paid	0.18	0.18	-	-	-	-	-	-	-	-	-

This table presents Denali Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Total Assets	1,374	1,154	1,460	1,404	1,604	553	662	487
Total Current Assets	864	1,064	1,372	897	1,496	430	481	410
Cash & Equivalents	175	127	218	293	507	79	77	218
Short-Term Investments	657	907	1,118	572	963	336	387	188
Prepaid Expenses	32	30	36	31	20	15	17	3.38
Plant, Property, & Equipment, net	55	46	44	39	41	47	25	15
Total Noncurrent Assets	455	44	44	468	68	76	156	62
Long-Term Investments	359	0.00	-	425	33	40	148	61
Noncurrent Note & Lease Receivables	48	0.00	-	-	-	-	-	-
Other Noncurrent Operating Assets	48	44	44	43	35	37	8.11	1.44
Total Liabilities & Shareholders' Equity	1,374	1,154	1,460	1,404	1,604	553	662	487
Total Liabilities	144	123	418	442	454	158	115	21
Total Current Liabilities	102	78	364	378	72	45	33	14
Accounts Payable	11	9.48	2.79	4.78	1.07	2.59	1.89	2.72
Accrued Expenses	91	68	67	-	-	-	-	5.36
Total Noncurrent Liabilities	42	45	54	64	382	113	82	6.76
Other Noncurrent Operating Liabilities	42	45	53	64	382	113	58	0.47
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,230	1,031	1,042	962	1,151	395	547	466
Total Preferred & Common Equity	1,230	1,031	1,042	962	1,151	395	547	466
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,230	1,031	1,042	962	1,151	395	547	466
Common Stock	2,767	2,147	2,020	1,610	1,505	820	775	658
Retained Earnings	-1,539	-1,116	-971	-645	-354	-426	-228	-192
Accumulated Other Comprehensive Income / (Loss)	2.02	0.64	-6.89	-2.50	-0.25	0.35	-0.65	-0.37

This table presents Denali Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,271	1,454	1,503	1,581	1,237	1,306	1,409	1,228
Total Current Assets	879	869	928	974	1,143	1,224	1,325	1,139
Cash & Equivalents	57	91	75	61	148	132	68	119
Short-Term Investments	761	746	821	876	961	1,059	1,220	987
Prepaid Expenses	61	32	32	37	34	33	37	32
Plant, Property, & Equipment, net	58	51	48	47	48	40	42	42
Total Noncurrent Assets	335	534	526	561	46	42	42	47
Long-Term Investments	236	445	451	491	7.91	-	-	0.00
Noncurrent Note & Lease Receivables	50	39	-	-	-	-	-	-
Other Noncurrent Operating Assets	49	50	75	70	38	42	42	47
Total Liabilities & Shareholders' Equity	1,271	1,454	1,503	1,581	1,237	1,306	1,409	1,228
Total Liabilities	149	136	116	126	118	119	443	416
Total Current Liabilities	92	87	75	83	71	69	391	361
Accounts Payable	8.46	9.59	14	12	12	15	11	8.98
Accrued Expenses	50	38	33	43	36	36	77	41
Current Deferred Revenue	17	16	10	13	-	-	-	-
Current Employee Benefit Liabilities	7.66	15	9.56	8.05	16	10	7.37	13
Other Current Liabilities	8.59	8.04	7.77	7.51	7.01	7.62	296	298
Total Noncurrent Liabilities	57	48	41	43	47	50	52	56
Other Noncurrent Operating Liabilities	57	48	41	43	47	50	52	56
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,123	1,318	1,387	1,455	1,118	1,187	967	811
Total Preferred & Common Equity	1,123	1,318	1,387	1,455	1,118	1,187	967	811
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,123	1,318	1,387	1,455	1,118	1,187	967	811
Common Stock	2,793	2,737	2,707	2,675	2,116	2,086	2,050	1,695
Retained Earnings	-1,672	-1,424	-1,317	-1,218	-997	-897	-1,081	-872
Accumulated Other Comprehensive Income / (Loss)	2.04	5.53	-2.66	-1.30	-0.65	-1.44	-2.52	-12

This table displays calculated financial ratios and metrics derived from Denali Therapeutics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	-100.00%	204.74%	122.90%	-85.50%	1,158.19%	-79.35%	0.00%	0.00%	0.00%
EBITDA Growth	-113.62%	32.22%	-18.66%	-490.46%	133.92%	-404.57%	50.61%	1.53%	0.00%
EBIT Growth	-147.76%	42.27%	-15.21%	-571.56%	129.42%	-359.73%	47.42%	-0.86%	0.00%
NOPAT Growth	-147.76%	42.27%	-15.21%	-434.48%	141.48%	-359.73%	48.56%	-3.10%	0.00%
Net Income Growth	-191.12%	55.45%	-12.19%	-508.49%	136.00%	-445.29%	58.90%	-1.77%	0.00%
EPS Growth	-142.45%	59.23%	-8.79%	-479.37%	130.43%	-430.77%	93.38%	56.34%	0.00%
Operating Cash Flow Growth	2.88%	-46.29%	-15.77%	-150.80%	374.55%	-402.45%	165.40%	-6.57%	0.00%
Free Cash Flow Firm Growth	10.57%	-56.57%	-18.66%	-165.17%	329.17%	-586.58%	151.18%	0.00%	0.00%
Invested Capital Growth	1,167.75%	98.79%	10.59%	6.62%	-483.02%	7.62%	-5,436.69%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	-3.02%	-2.02%	-86.21%	1,327.36%	-81.94%	3,607.23%	0.00%	0.00%
EBITDA Q/Q Growth	8.97%	-45.50%	-10.02%	-770.66%	130.64%	-172.08%	70.41%	0.00%	0.00%
EBIT Q/Q Growth	0.56%	-16.07%	-9.03%	-1,262.18%	126.23%	-164.16%	67.94%	0.00%	0.00%
NOPAT Q/Q Growth	0.56%	-16.07%	-9.03%	-913.52%	136.98%	-84.91%	67.94%	0.00%	0.00%
Net Income Q/Q Growth	1.10%	-16.71%	-7.74%	-1,082.85%	131.23%	-922.06%	84.02%	0.00%	0.00%
EPS Q/Q Growth	6.20%	-9.28%	-5.26%	-568.63%	128.38%	-213.64%	-18.18%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	4.12%	-7.83%	-3.02%	-157.44%	386.20%	-1,310.27%	181.62%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-1.14%	-3.22%	-1.08%	-184.42%	365.49%	-114.39%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	4.13%	-404.02%	0.33%	5.14%	-255.45%	6.76%	-16.77%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%
EBITDA Margin	0.00%	-67.75%	-304.58%	-572.14%	21.24%	-787.96%	-32.26%	0.00%	0.00%
Operating Margin	0.00%	-59.51%	-314.16%	-607.78%	18.69%	-799.10%	-35.90%	0.00%	0.00%
EBIT Margin	0.00%	-59.51%	-314.16%	-607.78%	18.69%	-799.10%	-35.90%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	-43.94%	-300.56%	-597.15%	21.19%	-740.74%	-28.06%	0.00%	0.00%
Tax Burden Percent	100.02%	100.02%	100.01%	98.25%	113.42%	92.70%	78.15%	100.00%	99.11%
Interest Burden Percent	86.74%	73.82%	95.66%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	1.31%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-37.40%	-14.01%	-32.52%	-27.51%	9.21%	-41.97%	-7.16%	-18.93%	0.00%
Cash Return on Invested Capital (CROIC)	-1,007.57%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-15.05%	-23.79%	-19.66%	5.81%	-35.09%	-8.07%	0.00%	0.00%
Return on Assets (ROA)	0.00%	-11.11%	-22.76%	-19.32%	6.59%	-32.52%	-6.31%	0.00%	0.00%
Return on Common Equity (ROCE)	-37.40%	-14.01%	-32.52%	-27.51%	9.21%	-41.97%	-7.16%	-18.93%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-34.38%	-14.09%	-31.27%	-30.20%	6.18%	-50.04%	-6.63%	-18.93%	0.00%
Net Operating Profit after Tax (NOPAT)	-341	-138	-239	-207	62	-149	-32	-63	-61
NOPAT Margin	0.00%	-41.66%	-219.91%	-425.44%	18.44%	-559.37%	-25.13%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-7.33%	-0.64%	-6.66%	-5.98%	0.94%	-9.07%	-0.70%	-10.74%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-27.74%	-13.36%	-22.88%	-	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	31.27%	83.42%	162.47%	17.97%	174.23%	25.05%	0.00%	0.00%
R&D to Revenue	0.00%	128.24%	330.74%	545.31%	63.34%	724.87%	110.86%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	159.51%	414.16%	707.78%	81.32%	899.10%	135.90%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-487	-197	-341	-296	63	-213	-46	-88	-87
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-478	-224	-330	-278	71	-210	-42	-84	-86
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.39	2.88	3.62	5.66	8.73	4.24	3.59	0.00	0.00
Price to Tangible Book Value (P/TBV)	2.39	2.88	3.62	5.66	8.73	4.24	3.59	0.00	0.00
Price to Revenue (P/Rev)	0.00	8.97	34.82	111.93	29.92	62.71	15.19	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	142.39	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.70%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	45.85	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	5.84	22.50	85.41	25.45	45.64	10.45	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	119.80	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	136.20	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	138.01	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	20.53	0.00	26.93	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	24.17	0.00	42.59	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.98	-1.14	-1.31	-1.32	-1.27	-1.13	-1.07	-1.00	0.00
Leverage Ratio	1.12	1.26	1.43	1.42	1.40	1.29	1.13	1.04	0.00
Compound Leverage Factor	0.97	0.93	1.37	1.42	1.40	1.29	1.13	1.04	0.00
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	10.11	13.87	4.63	6.54	14.38	4.87	10.52	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	8.46	13.65	3.77	2.37	20.86	9.48	14.67	28.92	0.00
Quick Ratio	8.14	13.27	3.67	2.29	20.58	9.16	14.16	28.68	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-383	-428	-273	-230	353	-154	32	-62	0.00
Operating Cash Flow to CapEx	-2,185.11%	-2,766.76%	-1,372.26%	-2,486.93%	13,445.95%	-845.90%	1,477.04%	-2,665.57%	-1,172.29%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.25	0.08	0.03	0.31	0.04	0.22	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	14.10	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	7.37	2.62	1.22	7.67	0.74	6.44	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	25.88	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	25.88	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	38	-3.56	-294	-329	-352	-60	-65	-1.18	0.00
Invested Capital Turnover	0.00	-2.22	-0.35	-0.14	-1.63	-0.42	-3.88	0.00	0.00
Increase / (Decrease) in Invested Capital	42	290	35	23	-292	4.98	-64	-1.18	0.00
Enterprise Value (EV)	1,741	1,931	2,441	4,156	8,542	1,218	1,350	0.00	0.00
Market Capitalization	2,933	2,966	3,777	5,447	10,044	1,673	1,962	0.00	0.00
Book Value per Share	$8.54	$7.46	$7.68	$7.88	$9.59	$4.11	$5.76	$31.13	$0.00
Tangible Book Value per Share	$8.54	$7.46	$7.68	$7.88	$9.59	$4.11	$5.76	$31.13	$0.00
Total Capital	1,230	1,031	1,042	962	1,151	395	547	466	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,192	-1,035	-1,336	-1,291	-1,502	-455	-612	-467	0.00
Capital Expenditures (CapEx)	16	13	18	8.50	3.10	18	3.39	2.88	6.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-70	-48	-328	-346	-46	-31	-16	-11	0.00
Debt-free Net Working Capital (DFNWC)	762	986	1,008	519	1,424	385	448	395	0.00
Net Working Capital (NWC)	762	986	1,008	519	1,424	385	448	395	0.00
Net Nonoperating Expense (NNE)	82	7.53	87	84	-9.24	48	3.78	25	25
Net Nonoperating Obligations (NNO)	-1,192	-1,035	-1,336	-1,291	-1,502	-455	-612	-467	0.00
Total Depreciation and Amortization (D&A)	8.99	-27	10	17	8.59	2.97	4.71	3.84	1.77
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-14.63%	-302.24%	-711.90%	-13.63%	-114.96%	-12.58%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	298.35%	929.72%	1,066.54%	424.23%	1,441.96%	346.90%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	298.35%	929.72%	1,066.54%	424.23%	1,441.96%	346.90%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.57)	($1.06)	($2.60)	($2.39)	$0.65	($2.07)	($0.39)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	164.47M	137.37M	125.53M	121.52M	108.97M	105.42M	95.29M	0.00	0.00
Adjusted Diluted Earnings per Share	($2.57)	($1.06)	($2.60)	($2.39)	$0.63	($2.07)	($0.39)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	164.47M	137.37M	125.53M	121.52M	108.97M	105.42M	95.29M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($2.07)	($0.39)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	145.22M	139.16M	136.68M	122.83M	108.97M	95.61M	92.62M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-351	-138	-239	-207	62	-149	-32	-63	-61
Normalized NOPAT Margin	0.00%	-41.66%	-219.91%	-425.44%	18.44%	-559.37%	-25.13%	0.00%	0.00%
Pre Tax Income Margin	0.00%	-43.93%	-300.54%	-607.78%	18.69%	-799.10%	-35.90%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3.82%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Denali Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	-100.00%	-100.00%	-100.00%	0.00%	-64.40%	460.45%	-16.61%	-17.83%	-32.66%
EBITDA Growth	-23.21%	27.03%	-8.84%	-177.35%	-6.28%	-69.79%	9.48%	373.96%	-88.91%	-41.45%	-26.13%
EBIT Growth	-23.67%	2.06%	-8.25%	-168.39%	2.57%	-25.85%	-10.16%	377.59%	-81.68%	-36.60%	-20.69%
NOPAT Growth	-23.67%	2.06%	-8.25%	-147.87%	2.57%	-25.85%	-5.87%	496.55%	-81.68%	-36.60%	-25.58%
Net Income Growth	-30.62%	3.95%	-7.89%	-154.00%	7.27%	-21.07%	3.82%	411.91%	-68.32%	-31.11%	-22.12%
EPS Growth	-14.71%	20.24%	12.50%	-145.38%	15.00%	-12.00%	14.29%	370.83%	-50.94%	-20.97%	-21.74%
Operating Cash Flow Growth	-15.71%	15.15%	32.31%	19.39%	-93.22%	-35.77%	-53.14%	-163.81%	18.45%	-10.95%	-37.68%
Free Cash Flow Firm Growth	66.91%	65.43%	67.64%	-21.19%	-720.00%	-252.95%	-196.06%	-11.25%	49.03%	-40.42%	-167.67%
Invested Capital Growth	147.16%	1,167.75%	3,017.35%	1,061.39%	108.67%	98.79%	100.40%	98.51%	-11.00%	10.59%	14.90%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-99.57%	736.98%	241.74%	188.93%	-93.22%
EBITDA Q/Q Growth	-11.90%	-26.79%	19.54%	1.08%	11.62%	-89.11%	-157.18%	235.92%	-13.71%	-0.82%	-73.05%
EBIT Q/Q Growth	-12.12%	-5.41%	-5.66%	0.95%	11.21%	-16.50%	-166.75%	241.11%	-14.69%	-1.98%	-68.20%
NOPAT Q/Q Growth	-12.12%	-5.41%	-5.66%	0.95%	11.21%	-16.50%	-146.72%	301.59%	-14.69%	1.99%	-75.01%
Net Income Q/Q Growth	-15.88%	-7.05%	-8.25%	2.73%	14.79%	-20.25%	-154.18%	267.04%	-11.25%	4.47%	-75.70%
EPS Q/Q Growth	-16.42%	-6.35%	-6.78%	13.24%	19.05%	-16.67%	-155.38%	262.50%	-6.67%	10.71%	-75.00%
Operating Cash Flow Q/Q Growth	-57.04%	-41.56%	35.17%	19.71%	-15.17%	-12.93%	22.80%	-92.46%	19.08%	-27.38%	-32.98%
Free Cash Flow Firm Q/Q Growth	-7.94%	-8.96%	3.38%	70.88%	-12.79%	-1.98%	-261.85%	-97.00%	51.45%	14.46%	-35.97%
Invested Capital Q/Q Growth	81.45%	4.13%	-8.85%	43.50%	883.89%	-404.02%	128.11%	98.71%	-9.52%	0.33%	-5.86%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-7,276.40%	54.82%	-337.56%	-998.57%	-2,861.65%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8,981.45%	57.96%	-343.80%	-1,024.45%	-3,020.12%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8,981.45%	57.96%	-343.80%	-1,024.45%	-2,902.47%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-7,841.59%	62.35%	-312.40%	-959.62%	-2,902.47%
Tax Burden Percent	100.00%	100.06%	100.00%	100.00%	100.00%	100.03%	100.00%	100.00%	100.00%	104.14%	100.00%
Interest Burden Percent	91.34%	88.32%	87.02%	84.93%	86.48%	90.10%	87.31%	107.57%	90.87%	89.95%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-35.21%	-37.40%	-35.09%	0.00%	-11.33%	-14.01%	-12.90%	-12.40%	-39.32%	-32.52%	-33.18%
Cash Return on Invested Capital (CROIC)	-829.92%	-1,007.57%	-2,010.20%	-951.31%	-1,739.95%	0.00%	-35,431.77%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,484.20%	15.31%	-25.55%	-77.58%	-239.98%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,168.92%	16.47%	-23.22%	-72.67%	-239.98%
Return on Common Equity (ROCE)	-35.21%	-37.40%	-35.09%	0.00%	-11.33%	-14.01%	-12.90%	-12.40%	-39.32%	-32.52%	-33.18%
Return on Equity Simple (ROE_SIMPLE)	-40.43%	0.00%	-32.42%	-30.26%	-9.43%	0.00%	-11.13%	-10.82%	-38.33%	0.00%	-37.29%
Net Operating Profit after Tax (NOPAT)	-102	-91	-86	-82	-82	-93	-80	170	-85	-74	-75
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-6,287.02%	57.96%	-240.66%	-717.11%	-2,114.08%
Net Nonoperating Expense Percent (NNEP)	-2.50%	-2.14%	-1.75%	-1.37%	-1.43%	-2.25%	-1.77%	1.10%	-2.02%	-1.90%	-2.28%
Return On Investment Capital (ROIC_SIMPLE)	-9.08%	-7.39%	-	-	-	-9.00%	-	-	-	-7.07%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,998.82%	8.88%	77.23%	228.69%	653.53%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	7,082.64%	33.16%	366.57%	895.76%	2,466.59%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9,081.45%	42.04%	443.80%	1,124.45%	3,120.12%
Earnings before Interest and Taxes (EBIT)	-146	-130	-123	-117	-118	-133	-114	170	-121	-105	-103
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-142	-127	-100	-125	-126	-174	-92	161	-119	-103	-102
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.76	2.39	3.16	2.39	1.95	2.88	2.54	3.40	3.26	3.62	4.67
Price to Tangible Book Value (P/TBV)	1.76	2.39	3.16	2.39	1.95	2.88	2.54	3.40	3.26	3.62	4.67
Price to Revenue (P/Rev)	0.00	0.00	0.00	2,613.56	9.60	8.97	8.32	11.77	31.04	34.82	34.20
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	13.36	45.85	79.19	49.09	50.50	0.00	1,468.25	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	1,550.39	4.77	5.84	5.04	8.30	18.34	22.50	24.21
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.96	-0.98	-0.98	-0.99	-1.12	-1.14	-1.15	-1.14	-1.32	-1.31	-1.35
Leverage Ratio	1.11	1.12	1.10	1.09	1.23	1.26	1.28	1.25	1.45	1.43	1.47
Compound Leverage Factor	1.01	0.99	0.96	0.93	1.07	1.14	1.12	1.35	1.32	1.29	1.47
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	6.49	10.97	17.46	16.40	13.08	14.05	14.24	21.18	3.78	5.16	5.03
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.56	8.46	9.98	12.46	11.79	13.65	16.06	17.65	3.39	3.77	3.16
Quick Ratio	8.90	8.14	9.61	12.02	11.34	13.27	15.58	17.17	3.29	3.67	3.07
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-143	-132	-122	-126	-432	-383	-376	-104	-53	-109	-127
Operating Cash Flow to CapEx	-2,588.97%	-1,644.05%	-1,522.63%	-1,905.98%	-5,284.65%	-4,414.18%	-4,224.52%	-1,934.51%	-2,110.62%	-1,498.52%	-942.91%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.20	0.25	0.28	0.26	0.07	0.08	0.08
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.03	6.64	7.37	7.59	8.74	2.54	2.62	2.71
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	69	38	36	40	28	-3.56	1.17	-4.16	-322	-294	-295
Invested Capital Turnover	0.00	0.00	0.00	0.07	-2.01	-2.22	-2.32	-2.43	-0.33	-0.35	-0.35
Increase / (Decrease) in Invested Capital	41	42	35	44	350	290	296	274	-32	35	52
Enterprise Value (EV)	920	1,741	2,888	1,964	1,408	1,931	1,718	2,849	1,861	2,441	2,680
Market Capitalization	1,974	2,933	4,170	3,311	2,836	2,966	2,835	4,040	3,149	3,777	3,786
Book Value per Share	$7.73	$8.54	$9.21	$9.73	$9.74	$7.46	$8.14	$8.67	$7.07	$7.68	$6.58
Tangible Book Value per Share	$7.73	$8.54	$9.21	$9.73	$9.74	$7.46	$8.14	$8.67	$7.07	$7.68	$6.58
Total Capital	1,123	1,230	1,318	1,387	1,455	1,031	1,118	1,187	967	1,042	811
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,054	-1,192	-1,282	-1,347	-1,428	-1,035	-1,117	-1,191	-1,288	-1,336	-1,106
Capital Expenditures (CapEx)	5.08	5.09	3.88	4.79	2.15	2.24	2.07	5.85	2.79	4.85	6.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-31	-70	-55	-42	-46	-48	-38	-36	-354	-328	-328
Debt-free Net Working Capital (DFNWC)	787	762	782	854	891	986	1,072	1,155	934	1,008	778
Net Working Capital (NWC)	787	762	782	854	891	986	1,072	1,155	934	1,008	778
Net Nonoperating Expense (NNE)	31	24	21	17	19	27	20	-13	25	25	28
Net Nonoperating Obligations (NNO)	-1,054	-1,192	-1,282	-1,347	-1,428	-1,035	-1,117	-1,191	-1,288	-1,336	-1,106
Total Depreciation and Amortization (D&A)	3.21	2.62	23	-8.12	-8.35	-42	22	-9.25	2.19	2.66	1.45
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	-3,330.23%	-15.53%	-14.63%	-11.02%	-10.57%	-349.26%	-302.24%	-296.49%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	67,391.48%	301.63%	298.35%	314.45%	336.54%	920.61%	929.72%	702.71%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	67,391.48%	301.63%	298.35%	314.45%	336.54%	920.61%	929.72%	702.71%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.78)	($0.67)	($0.63)	($0.59)	($0.68)	($0.88)	($0.72)	$1.34	($0.80)	($0.75)	($0.84)
Adjusted Weighted Average Basic Shares Outstanding	171.22M	164.47M	169.46M	168.83M	149.40M	137.37M	137.64M	137.05M	136.52M	125.53M	123.47M
Adjusted Diluted Earnings per Share	($0.78)	($0.67)	($0.63)	($0.59)	($0.68)	($0.84)	($0.72)	$1.30	($0.80)	($0.75)	($0.84)
Adjusted Weighted Average Diluted Shares Outstanding	171.22M	164.47M	169.46M	168.83M	149.40M	137.37M	137.64M	140.93M	136.52M	125.53M	123.47M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	145.28M	145.22M	143.92M	143.17M	142.61M	139.16M	138.20M	137.42M	136.89M	136.68M	135.81M
Normalized Net Operating Profit after Tax (NOPAT)	-102	-91	-86	-82	-93	-93	-80	119	-85	-74	-75
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-6,287.02%	40.57%	-240.66%	-717.11%	-2,114.08%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-7,841.59%	62.35%	-312.40%	-921.49%	-2,902.47%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Denali Therapeutics' Financials

When does Denali Therapeutics's financial year end?

According to the most recent income statement we have on file, Denali Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Denali Therapeutics' net income changed over the last 8 years?

Denali Therapeutics' net income appears to be on an upward trend, with a most recent value of -$422.77 million in 2024, rising from -$86.65 million in 2016. The previous period was -$145.22 million in 2023. See where experts think Denali Therapeutics is headed by visiting Denali Therapeutics' forecast page.

What is Denali Therapeutics's operating income?

Denali Therapeutics's total operating income in 2024 was -$487.34 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $487.34 million

How has Denali Therapeutics revenue changed over the last 8 years?

Over the last 8 years, Denali Therapeutics' total revenue changed from $0.00 in 2016 to $0.00 in 2024, a change of 0.0%.

How much debt does Denali Therapeutics have?

Denali Therapeutics' total liabilities were at $144.50 million at the end of 2024, a 17.5% increase from 2023, and a 590.5% increase since 2017.

How much cash does Denali Therapeutics have?

In the past 7 years, Denali Therapeutics' cash and equivalents has ranged from $77.12 million in 2018 to $507.14 million in 2020, and is currently $174.96 million as of their latest financial filing in 2024.

How has Denali Therapeutics' book value per share changed over the last 8 years?

Over the last 8 years, Denali Therapeutics' book value per share changed from 0.00 in 2016 to 8.54 in 2024, a change of 854.4%.

Related Companies

This page (NASDAQ:DNLI) was last updated on 5/27/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Financials

Frequently Asked Questions About Denali Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Denali Therapeutics (DNLI) Financials

Annual Income Statements for Denali Therapeutics

Quarterly Income Statements for Denali Therapeutics

Annual Cash Flow Statements for Denali Therapeutics

Quarterly Cash Flow Statements for Denali Therapeutics

Annual Balance Sheets for Denali Therapeutics

Quarterly Balance Sheets for Denali Therapeutics

Annual Metrics And Ratios for Denali Therapeutics

Quarterly Metrics And Ratios for Denali Therapeutics

Frequently Asked Questions About Denali Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools